Clee Medical
Clee Medical is pioneering advancements in neurotechnology by developing innovative imaging and sensing tools that enhance precision in neurosurgery. Their mission focuses on improving surgical outcomes and increasing capacity through real-time, ultra-high-resolution imaging solutions that integrate seamlessly with existing surgical workflows. By addressing the limitations of traditional MRI imaging, Clee Medical aims to redefine neuro-intervention and enhance patient safety, positioning itself as a leader in the rapidly evolving field of neurotech.
Clee Medical
Clee Medical is pioneering advancements in neurotechnology by developing innovative imaging and sensing tools that enhance precision in neurosurgery. Their mission focuses on improving surgical outcomes and increasing capacity through real-time, ultra-high-resolution imaging solutions that integrate seamlessly with existing surgical workflows. By addressing the limitations of traditional MRI imaging, Clee Medical aims to redefine neuro-intervention and enhance patient safety, positioning itself as a leader in the rapidly evolving field of neurotech.
TL;DR
Founded: October 2024 (Wyss Center spin-out)
Headquarters: Geneva, Switzerland
Product: Neuro Access — real-time, ultra-high-resolution intraoperative imaging + AI navigation
Founders / Leadership: Matthew Lapinski (Co-founder & CEO); Abed Hammoud (Co-founder & CTO)
Funding: Early-stage grants/non-dilutive support (Venture Kick, W. A. de Vigier, Innosuisse, Future of Health Grant)
Related Companies
| Company |
|---|
 |
 |
 |
 |
 |
Company Overview
Problem Domain
Current intraoperative imaging and targeting methods in neurosurgery have limitations in resolution, real-time feedback, and vascular/tissue detection that can affect targeting accuracy and patient safety.
Founded
2024
Industry
Biotechnology
Tech Stack
Funding Track Record
Listed as a named funder/supporter
CHF 120000
Reported grant award
Reported grant support (joint with Bern University of Applied Sciences)
Selected recipient of Future of Health Grant 2025
Investor Signal
“Company has received multiple non-dilutive grants and awards (Venture Kick, W. A. de Vigier, Innosuisse, Future of Health Grant)”